Gansu Longshenrongfa Pharmaceutical Industry Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.24, indicating a relatively conservative leverage position. Its liquidity position is assessed as medium, with a current ratio of 1.43, suggesting moderate short-term liquidity coverage. The price-to-book ratio of 3.73 and price-to-tangible-book ratio of 3.73 indicate that the market is valuing the company's equity at a premium relative to its book value. The company's market capitalization of 2.64 billion CNY and a price-to-earnings ratio of 60.05 suggest a high valuation relative to earnings. In terms of profitability, the company's return on equity of 6.2% and return on assets of 3.15% are below the typical thresholds for high-performing pharmaceutical firms. The operating margin, calculated as operating income of 98.5 million CNY on revenue of 886.96 million CNY, is 11.1%, which is in line with the industry median for mid-sized pharmaceutical companies. The gross margin of 68.1% (603.76 million CNY gross profit on 886.96 million CNY revenue) is strong, indicating efficient production and cost control. The company's geographic and segment exposure is not disclosed in the available data, but the revenue concentration in a single business line (pharmaceuticals) suggests a high degree of operational focus. The company's revenue of 886.96 million CNY is modest compared to industry leaders, and the lack of segment-specific revenue data limits the ability to assess diversification. The company's growth trajectory is not clearly defined in the available data, but the free cash flow of 49.18 million CNY and capital expenditure of -43.36 million CNY suggest a net cash outflow for investment. The operating cash flow of -6.54 million CNY indicates a cash burn in operations, which may be a concern for long-term sustainability. The outlook for the current fiscal year is not provided, but the company's net income of 43.95 million CNY on revenue of 886.96 million CNY suggests a net margin of 5.0%, which is below the industry median. The company's risk profile includes a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The dilution risk is assessed as low, with no near-term pressure expected, and no dilution sources identified in the available data. The company's capital structure and financial performance suggest a moderate risk profile, with no significant red flags in the risk assessment. Recent events and filings are not disclosed in the available data, but the company's financial performance and risk profile suggest a stable but not high-growth business model. The lack of recent events or significant changes in the company's operations or financials indicates a relatively stable business environment.